gp100: ES209-217(210M) Peptide
A synthetic peptide vaccine consisting of amino acids 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen with an endoplasmic reticulum signal sequence (ES) to increase binding activity. Vaccination with gp100:ES209-217(210M) may stimulate the host immune system to mount a cytotoxic T lymphocyte response against tumor cells positive for gp100, resulting in decreased tumor growth. (NCI04) [ ]
Term info
gp100: ES209-217(210M) Peptide
- gp100: ES209-217 (210M)
- gp100: ES209-217(210M) Peptide
http://purl.obolibrary.org/obo/NCIT_C2386
gp100_ES209-217_210M
705434
gp100: ES209-217(210M) Peptide
Pharmacologic Substance, Amino Acid, Peptide, or Protein
C1711110
C2763
Term relations
- Antineoplastic Vaccine
- Peptide Vaccine
- Chemical_Or_Drug_Has_Physiologic_Effect some T-Cell Activation
- Chemical_Or_Drug_Affects_Cell_Type_Or_Tissue some Cytotoxic T-Lymphocyte
- Chemical_Or_Drug_Has_Mechanism_Of_Action some Antigen Sensitization
- Chemical_Or_Drug_Affects_Abnormal_Cell some Melanoma Cell
- Chemical_Or_Drug_Has_Physiologic_Effect some Immunopotentiation